Ligand Pharmaceuticals Incorporated
LGND
$104.97
$0.350.34%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 27.28% | -0.76% | -25.82% | -41.92% | -33.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.28% | -0.76% | -25.82% | -41.92% | -33.09% |
| Cost of Revenue | -7.28% | -44.89% | -54.51% | -60.75% | -60.58% |
| Gross Profit | 39.86% | 26.56% | -6.20% | -28.32% | -10.31% |
| SG&A Expenses | 48.99% | 1.64% | -13.16% | -23.34% | -24.65% |
| Depreciation & Amortization | -2.07% | -2.41% | -3.41% | -2.62% | -1.70% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.62% | -16.24% | -28.48% | -36.53% | -37.12% |
| Operating Income | 134.41% | 359.77% | 78.72% | -109.24% | 223.38% |
| Income Before Tax | -96.04% | -16.81% | -44.32% | 20.74% | 76.78% |
| Income Tax Expenses | -33.44% | -72.64% | -79.95% | -48.90% | -76.13% |
| Earnings from Continuing Operations | -107.49% | 114.46% | 2.75% | 87.72% | 1,131.21% |
| Earnings from Discontinued Operations | -- | 100.00% | 100.00% | 100.00% | 94.08% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.73% | 174.52% | 55.18% | 301.89% | 256.33% |
| EBIT | 134.41% | 359.77% | 78.72% | -109.24% | 223.38% |
| EBITDA | 25.72% | 68.15% | -7.08% | -43.88% | -14.82% |
| EPS Basic | -101.63% | 172.62% | 53.72% | 290.26% | 253.69% |
| Normalized Basic EPS | -197.88% | -335.06% | -339.47% | -86.61% | 166.88% |
| EPS Diluted | -105.55% | 198.62% | 59.04% | 318.38% | 246.74% |
| Normalized Diluted EPS | -203.43% | -286.92% | -372.60% | -86.10% | 167.10% |
| Average Basic Shares Outstanding | 5.74% | 4.43% | 3.65% | 3.17% | 2.54% |
| Average Diluted Shares Outstanding | 3.93% | 3.25% | 2.12% | 2.68% | 4.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |